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Abstract The prevalence of cardiovascular diseases is
rising. Therefore, adequate risk prediction and identiﬁca-
tion of its determinants is increasingly important. The
Rotterdam Study is a prospective population-based cohort
study ongoing since 1990 in the city of Rotterdam, The
Netherlands. One of the main targets of the Rotterdam
Study is to identify the determinants and prognosis of
cardiovascular diseases. Case ﬁnding in epidemiological
studies is strongly depending on various sources of follow-
up and clear outcome deﬁnitions. The sources used for
collection of data in the Rotterdam Study are diverse and
the deﬁnitions of outcomes in the Rotterdam Study have
changed due to the introduction of novel diagnostics and
therapeutic interventions. This article gives the methods for
data collection and the up-to-date deﬁnitions of the cardiac
outcomes based on international guidelines, including the
recently adopted cardiovascular disease mortality deﬁni-
tions. In all, detailed description of cardiac outcome deﬁ-
nitions enhances the possibility to make comparisons with
other studies in the ﬁeld of cardiovascular research and
may increase the strength of collaborations.
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Introduction
Despite major advances in prevention and treatment, the
prevalence of cardiovascular diseases (CVD) is rising [1,
2]. Nowadays, the majority of healthy adults will be con-
fronted with some form of CVD during their lifetime and
still heart disease is the leading cause of death in the
western world, claiming approximately one out of every
ﬁve lives [2]. Therefore, the continued search for deter-
minants and predictors of occurrence and prognosis of
CVD is of paramount importance.
The Rotterdam Study is a prospective population-based
cohort study ongoing since 1990 in a suburb of the city of
Rotterdam, The Netherlands. The original cohort com-
prised of 7,983 inhabitants, aged 55 years or over and
living in the well-deﬁned Ommoord city district. The
participants undergo repeated extensive examinations
every 3–4 years at the Rotterdam Study research center,
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DOI 10.1007/s10654-012-9668-8located in the middle of the study area. They are followed
for a variety of diseases that are frequent in the general
population. At initiation, the study focused on cardiovas-
cular, neurological, ophthalmological, and endocrine dis-
eases. The rationale and design of the Rotterdam Study
have been described extensively in EJE two decades ago
[3]. However, over the years the original cohort has been
extended twice, the scope has been broadened, and the
characteristics of repeated examinations have changed. As
of December 2008, 14,926 subjects aged 45 years or over
comprise the Rotterdam Study cohort. Therefore, its
objectives and design have been updated regularly in this
journal [4–7]. Parallel to extensions in the design of the
Rotterdam Study, medical technology has advanced and
clinical presentation of heart disease is evolving.
Within the Rotterdam Study, multiple cardiac outcomes
are considered, namely recognized and unrecognized
myocardial infarction (MI), myocardial revascularization,
coronary heart disease (CHD) mortality, heart failure, atrial
ﬁbrillation (AF), and sudden cardiac death (SCD). The
sources used for collecting the data are diverse and up until
now their corresponding methods and the deﬁnitions of
various cardiac outcomes in the Rotterdam Study have not
been reported combined together in an overview. Further-
more, implementation of novel diagnostics and therapeutic
interventions in everyday cardiac care has urged us to
change deﬁnitions since our earliest reports on prevalence
and incidence of MI and CHD [8–10]. Above all, in today’s
era of large transatlantic collaborations in epidemiologic
research comparability of outcome deﬁnitions has gained
importance [11, 12]. In this article the methods of data
collection and up-to-date deﬁnitions of the cardiac out-
comes in the Rotterdam Study will be presented.
Methods of data collection
Dutch health care system
In order to understand the methods of data collection used in
theRotterdamStudyabriefintroductionintotheDutchhealth
care system is essential. Primary care, provided by general
practitioners (GPs), plays a central role in the health care in
The Netherlands. In The Netherlands there are almost 11,000
practicing GPs, who each have had 3 years of specialist
traininginfamilymedicine.AllDutchinhabitantscanregister
at a single general practice of choice. The GPs act as the
gatekeepers to hospital care and must give their approval
before patients can get referred to a medical specialist. In
doing so, the vast majority of problems presented in primary
care are handled by the GPs themselves [13].
Fordecades,emergencyandafter-hourscareishandledby
primarycarecooperatives.Inorder toprovide adequateafter-
hours care, full electronic exchange of patient data is of great
importance. Therefore, virtually all GPs in The Netherlands
use computer-based GP information systems based on
requirements set by the professional organizations of Dutch
general practice [Dutch GP Society (NHG) and Nationwide
Association of GPs (LVH)]. These computer systems have
been designed speciﬁcallyfor use inprimary care and consist
of a set of speciﬁc modules (e.g. medical, electronic com-
munication,prescription,ﬁnancial).Usingthedigitalsystems,
all encounters in primary practice are coded using the Inter-
national Classiﬁcation of Primary Care (ICPC) [14, 15]. As
discussed above, Dutch GPs have a coordinating role in the
overallhealthcareutilizationprocessoftheirpatientsenlisted.
Theyrefertheirpatientstomedicalspecialistsandarereported
back on every hospital admission and results from outpatient
contacts with medical specialists, preferably using electronic
communication [16]. Further details on the structure of the
health care system in The Netherlands and the use of elec-
tronic medical records have been described in detail [13,
17–20].
With regards to concerns of general accessibility to
medical care in The Netherlands, insurance status is not
allowed to be considered in referral of patients. Cardiac
hospital care, including invasive procedures, is covered by
the basic health care insurance plan in The Netherlands,
which is obligatory by law [17, 18].
Assessment of cardiovascular disease status at baseline
Upon entrance in the Rotterdam Study cohort, baseline
CVD status of each participant is ascertained in the fol-
lowing way. During a baseline home interview, trained
nonmedical interviewers administer a standardized ques-
tionnaire to obtain information on medical history (e.g. MI,
myocardial revascularization) and health status (e.g. chest
discomfort, breathlessness), and labels of current medica-
tion are copied (both prescription and over-the-counter
usage). Drug use is coded according to the Anatomical
Therapeutic Chemical (ATC) classiﬁcation index [21].
Questions on indication of cardiovascular medication and
breathlessness were lacking at the start of the Rotterdam
Study, but have subsequently been added. Consequently,
these questions were asked in most (70%) of the partici-
pants at baseline of the original Rotterdam Study cohort.
After the interview, the participants are invited to visit the
research center where they undergo a physical examination
in some detail by one of the study physicians and various
tests are performed [e.g. resting electrocardiogram (ECG),
echocardiography]. In addition to these examinations,
information on prevalent disease status is obtained by
accessing data from the Nationwide Medical Registry
(LMR, sourced by Dutch Hospital Data, Utrecht, The
Netherlands). This is a national registration on all primary
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123and secondary hospital discharge diagnoses of Dutch
inhabitants, with linkage on the basis of zip code, date of
birth, gender, and GP. Records from this registry are linked
to the study database. For potential events identiﬁed in this
registry, copies of hospital discharge letters and ECGs are
requested. Most importantly, clinical information on pre-
valent CVD status is obtained from the GPs for each par-
ticipant: the entire medical records of the GPs are hand
screened at the GPs’ ofﬁce by trained research assistants.
Using the aforementioned sources (interview, examination
at the research center, Nationwide Medical Registry, and
full screening of GPs’ records), disease status at baseline is
available for all participants of the Rotterdam Study. An
overview of the sources used for ascertaining disease status
at baseline is presented in Table 1.
Clinical follow-up
Follow-up starts after the baseline home interview of each
individual participant. Data on clinical cardiovascular
outcomes are collected continuously through an automated
follow-up system. The follow-up system involves auto-
mated digital linkage of the study database to digital ﬁles
from GPs in the study area. On a weekly basis, all ICPC
codes of diagnoses of interest made by the GPs and med-
ical specialists in study participants are entered to the
Rotterdam Study database. Moreover, the entire medical
record of each participant living in the research area is
checked by hand on a regular basis at the GPs’ ofﬁce by
trained research assistants for diagnoses of interest. This is
the primary source of information on CVD events, since all
letters of medical specialists, discharge reports in case of
hospitalization, and ECGs are copied by the research
assistants. Subsequently, all the collected information is
compared to the ICPC codes entered to the study database
for each individual participant. This is done in order to
make sure no clinical information on potential events is
missed out. Additional information is obtained from the
hospitals in case the automated follow-up system or med-
ical records contain insufﬁcient information. Medical
records of the participants under the care of nursing home
physicians or GPs working outside the study area are
checked annually for potential events. Furthermore, before
every repeat examination the participants are interviewed
on the occurrence of cardiac events since their last visit to
the research center.
With respect to the vital status of all participants,
information is obtained on a weekly basis from the central
registry of the municipality in Rotterdam and through the
digital linkage with GPs working in the study area. For
participants living outside the research area, the GPs are
the primary source of information, complemented by the
municipality records in the place of residence. After noti-
ﬁcation, cause and circumstances of death are established
Table 1 Sources of data in the Rotterdam Study
Source Data obtained on disease status at
study baseline
Data obtained on occurrence of outcomes during
follow-up
Regular checks of medical records at the GPs’
ofﬁce
Full medical history Intercurrent medical history
Hospital discharge letters Intercurrent hospital discharge letters
Reports on outpatient contacts with
medical specialists
Intercurrent reports on outpatient contacts with
medical specialists
Previous ECGs Intercurrent ECGs
Cause and circumstances of death
Continuous linkage of the study database with
GPs’ digital ﬁles
NA ICPC codes of all diagnoses made
Date of death
Home interviews Medical history Intercurrent medical history
Current health status Current health status
Current medication use Current medication use
Research center visits Resting ECG Resting ECG
Physical examination
Pharmacy prescription records Current medication use Continous monitoring of all prescriptions ﬁlled
Nationwide Medical Registry (LMR) History of hospital discharge
diagnoses for any outcome of interest
Intercurrent hospitalization with AF or atrial
ﬂutter
Municipality records NA Date and place of death
Hospitals Hospital discharge letters Hospital discharge letters
Previous ECGs Intercurrent ECGs
GP general practitioner, ECG electrocardiogram, NA not applicable, ICPC International Classiﬁcation of Primary Care, AF atrial ﬁbrillation
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123by requesting information from the medical records of the
GPs or nursing home physicians.
As of January 1991 onwards all drug prescriptions dis-
pensed to participants by seven fully automated pharmacies
in the study area are routinely stored in the database. At
baseline, nearly all (99.7%) participants were registered at
one of these pharmacies. This data consists of information
on the date of delivery, the total amount of drug units per
prescription, the prescribed daily number of units, product
name of the drugs, and the ATC-code [21, 22].
Table 1 provides an overview of the sources used for
obtaining information on the occurrence of cardiac out-
comes during follow-up.
Electrocardiography
At baseline and at each follow-up visit to the research
center, every participant has a 10 s 12-lead resting ECG
(on average 8-10 beats) recorded using an ACTA Gnosis
IV ECG recorder (Esaote Biomedica, Florence, Italy) at a
sampling frequency of 500 Hz and stored digitally. All
ECGs are processed by the standardized Modular ECG
Analysis System (MEANS) to obtain ECG measurements
and interpretation. The ECGs are analyzed off-line using
MEANS. The MEANS program has been evaluated
extensively and determines common onsets and offsets for
all 12 leads together on one representative averaged beat,
with the use of template matching techniques [23–27].
Ethics approval
The Rotterdam Study has been approved by the institu-
tional review board (Medical Ethics Committee) of the
Erasmus Medical Center and by the review board of The
Netherlands Ministry of Health, Welfare, and Sports. The
approval has been renewed every 5 years.
Informed consent
Participants provided written informed consent to partici-
pate in the study and to obtain information from their
treating physicians, separately. The latter includes per-
mission to obtain information from the GP, medical spe-
cialists, and pharmacists.
Event adjudication
For each outcome two cardiovascular research physicians
independently classify information on occurrence, certainty,
and date of onset of all data collected on potential events
according to the corresponding deﬁnitions below. Cases on
which the research physicians disagree are discussed in order
toreachconsensusinaseparatesession.Afterwards,apanelof
medical specialists in CVD reviews potential events for each
diagnosis separately. This panel consists of a cardiologist
(J.W.D.), two geriatricians (F.U.S.M.-R. and G.Z.), and a GP
experiencedincardiacdisease(J.H.).Themedicalspecialist’s
judgmentisconsidereddecisive.Theresearchphysiciansand
the medical specialists base their decisions on the same data.
This procedure is similar for both prevalent and incident
outcomes.
Deﬁnitions of cardiac outcomes
Within the Rotterdam Study eight highly prevalent cardiac
outcomes are considered subdivided into three categories,
namely CHD, heart failure, and cardiac arrhythmias
(Table 2).
Coronary heart disease
Myocardial infarction
The triad of chest pain, ECG abnormalities, and rise of
cardiac enzymes has been a generally accepted deﬁnition
of acute MI for many years. However, during the past
decades development of more sensitive and speciﬁc blood
markers (e.g. creatinin kinase MB, troponins) and
enhanced imaging techniques allow for detection of smal-
ler MIs. Widespread introduction of troponin testing in The
Netherlands happened around the turn of the century and
took several years to be fully implemented in the hospitals
in the research area [28]. This has had implications for
adjudication of MIs in the Rotterdam Study. Accordingly,
clinical practice, as well as epidemiological research
required a more precise deﬁnition of MI [29].
Methods on follow-up and event adjudication of pre-
valent and incident MI for the Rotterdam Study have been
described previously in brief [30]. The diagnosis of MI is
Table 2 Cardiac outcomes in the Rotterdam Study
Categories Underlying outcomes
Coronary heart disease MI
Unrecognized MI
Myocardial revascularization
CHD mortality
Overall CHD
Heart failure Heart failure
Cardiac arrhythmia Atrial ﬁbrillation and atrial ﬂutter
Sudden cardiac death
MI myocardial infarction, CHD coronary heart disease
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123classiﬁed as deﬁnite, probable, possible or unlikely. Deﬁ-
nite MI is deﬁned as pathology ﬁndings of an acute MI
within 28 days of death, or a rise/fall in cardiac biomarkers
and/or objective indicative ECG changes, and preferably
the presence of symptoms or signs (e.g. cardiac pain, car-
diogenic shock). Also, for deﬁnite MI, the diagnosis has to
have been made by a medical specialist, preferably a car-
diologist or an internist. If the MI was diagnosed by a GP
or a nursing home physician it is classiﬁed as probable. MI
is classiﬁed as possible when one of the criteria for prob-
able or deﬁnite MI cannot be met. MI is considered unli-
kely if symptoms or signs are present, but objective
evidence showing myocardial necrosis is lacking.
Accordingly, diagnoses of unstable angina, acute coronary
syndromes, and invasive procedure related ischemia are
also considered as MI events whenever they are accom-
panied by a signiﬁcant rise in cardiac biomarkers. Thereby,
the current deﬁnition of MI in the Rotterdam Study
includes the clinical type 1, 2, 4a, 4b, and type 5 MI as
deﬁned in the endorsed universal deﬁnition of MI [29]. In
accordance with the international epidemiological CHD
case deﬁnitions, only deﬁnite and probable cases are
included in the Rotterdam Study deﬁnition, unless other-
wise noted [31]. For participants of the original Rotterdam
Study cohort, the presence of MI at baseline is based on
veriﬁcation of either self-reported MI or ECG abnormali-
ties indicative of prior MI. In subsequent cohorts, the
medical records of all participants are screened for pre-
valent MI, regardless of their self-reported history or ECG
abnormalities. The presence of MI during follow-up is
based on clinical information from the medical records.
The date of incident MI is deﬁned as the day of the ﬁrst
occurrence of symptoms suggestive of MI.
Unrecognized myocardial infarction
Unrecognized MI, although prevalent, is not always con-
sidered as an outcome in epidemiologic studies on CHD,
since determining an exact date of occurrence of the MI is
impossible by deﬁnition [30]. Therefore, unrecognized MI
is not included as an outcome in studies on the occurrence
of CHD in the Rotterdam Study, unless otherwise noted.
However, separate studies within the framework of the
Rotterdam Study have been conducted on the prognosis of
this type of presentation of CHD [32–34].
Methods on deﬁnition of prevalent and incident unrecog-
nized MI within the Rotterdam Study have been summarized
previously [30, 34]. This deﬁnition is in accordance with the
criteria for ‘prior MI’ (type 3) deﬁned by the international
TaskForcefortheRedeﬁnitionofMI,asfollowsindetail[29].
AtbaselineoftheRotterdamStudyallparticipantswereasked
whether they had ever experienced a heart attack and who
established the diagnosis. Afterwards, an ECG was obtained
and analyzed using MEANS as described above. To deter-
mine MI, MEANS uses a comprehensive set of criteria that
partlyderivefromTheMinnesotaCode[35,36].Pathological
Q-waves are central in the diagnosis of MI using MEANS,
next to auxiliary criteria, such as QR-ratio and R-wave pro-
gression.Acardiologistwithexpertiseinelectrocardiography,
whose judgment was considered ﬁnal, reviewed all cases that
were classiﬁed by MEANS as possible, probable, or deﬁnite
MI.AtbaselineoftheRotterdamStudy,unrecognizedMIwas
considered to be present in all participants with conﬁrmed
ECG characteristics matching a MI, but without documented
history or self-reported MI. An incident unrecognized MI is
considered to have occurred if there is conﬁrmed electrocar-
diographic evidence of MI on follow-up examinations at the
research center, given the absence of an incident clinically
recognized MI at baseline or during follow-up. The unrec-
ognizedMIisconsideredtohaveoccurredinthemiddleofthe
time interval between the examination at which the unrec-
ognized MI is detected and the examination before that.
Myocardial revascularization
Invasive myocardial revascularization is an established
treatment for acute MI, relief of unstable angina, and
medically intractable stable angina. Furthermore, patients
with symptomatic or asymptomatic severe coronary artery
disease beneﬁt from myocardial revascularization by
improving survival [37]. Especially during the past decade,
a great number of novel and hybrid cardiac interventions,
and other transcatheter interventions have been introduced
[37, 38].
Within the Rotterdam Study data is collected on incident
coronary artery bypass grafting (CABG) and percutaneous
coronary interventions (PCIs) for atherosclerotic CHD,
separately. For PCI, previously termed percutaneous
transluminal coronary angioplasty, the following inter-
ventions are considered: coronary stenting, coronary bal-
loon angioplasty, coronary recanalization, intracoronary
thrombosuction, and (although very rare) intracoronary
laser and brachytherapy. CABG and PCI are also adjudi-
cated for combined cardiopulmonary surgery and other
combined or hybrid cardiac procedures [37, 38]. Any
attempt of revascularization is adjudicated, regardless of
success, given the indication is still present at the time of
the attempt. For participants of the original Rotterdam
Study cohort, the presence of myocardial revascularization
at baseline is based on self-reported CABG or PCI, veriﬁed
by clinical data from the medical records. In subsequent
cohorts, the medical records of all participants are screened
for prevalent myocardial revascularization procedures,
regardless of their self-reported history. The presence of
CABG and PCI during follow-up is based on clinical
information from the medical records. The date of incident
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123myocardial revascularization is obtained from the hospital
discharge letters.
As mentioned before, myocardial revascularization
procedures are available to everyone in The Netherlands,
regardless of insurance status. Myocardial revasculariza-
tion is fully covered by the basic health care insurance in
The Netherlands, which is obligatory by law [17, 18].
Coronary heart disease mortality
Fatal CHD is often an unheralded presentation of pre-
symptomatic coronary artery disease and is mainly attrib-
uted to sudden death, ischemic heart failure, and sequelae
of a MI [39]. Originally, the CHD mortality deﬁnitions in
the Rotterdam Study have been based on the International
Classiﬁcation of Diseases, 10th revision (ICD-10) codings
[40, 41]. Recently, a classiﬁcation used in other large
cohort studies with speciﬁc focus on CVD has been
adopted in order to improve the quality of the outcome data
and enhance comparability with other epidemiological
studies. This system is a marginally adapted classiﬁcation
applied by both the Cardiovascular Health Study and the
Atherosclerosis Risk in Communities Study [42–45]. From
2003 onward, this classiﬁcation has served as a basis for
the endorsed international case deﬁnition for out-of-hos-
pital CHD mortality in epidemiologic studies [31].
As a ﬁrst step, all deaths (both cardiovascular and
noncardiovascular) in the Rotterdam Study are adjudicated
based on ICD-10 codes. Subsequently, all available clinical
information for each potential new fatal CHD and CVD
case is reviewed by the research physicians in order to
ascertain the underlying cause of death and adjudicate a
CHD or CVD mortality category. The underlying deﬁni-
tions for the CHD and CVD mortality categories are pre-
sented in Table 3. CVD mortality is subdivided into the
following hierarchical categories: CHD (deﬁnite fatal MI,
deﬁnite fatal CHD, and possible fatal CHD), nontraumatic
cerebrovascular disease, other atherosclerotic disease, and
other CVD. Within the Rotterdam Study, none of the
deaths are classiﬁed as due to heart failure. The classiﬁ-
cation system used in the Rotterdam Study focuses on the
underlying etiology, rather than the mode of death: i.e.
participants dying with decompensated heart failure are
mostly classiﬁed as deaths being from CHD or valvular
heart disease. In rare cases where no possible underlying
etiology of heart failure can be established from the med-
ical records, these deaths are classiﬁed as being from other
CVD. The date of death is established from the medical
records or municipality records.
Coronary heart disease
The many forms of presentation of CHD make up for many
possibilities of combining these into an overall disease
outcome. The deﬁnition of combined CHD outcomes may
depend on the research question at hand.
Within the Rotterdam Study two different combined
outcomes have been used as described previously [40].
First, ‘total CHD’ is deﬁned as a combined outcome of
myocardial revascularization (as a proxy for signiﬁcant
Table 3 Rotterdam Study cardiovascular mortality classiﬁcation and deﬁnitions for underlying cause of death
Mortality
categories(hierarchical)
Underlying cause
of death
1. Coronary heart disease Deﬁnite fatal MI No known nonatherosclerotic cause, and deﬁnite MI within 28 days of death
Deﬁnite fatal CHD No known nonatherosclerotic cause, and at least one of the following:
cardiac pain within 72 h of death or a history of ischemic heart
disease in the absence of signiﬁcant valvular heart disease
or nonischemic cardiomyopathy
Possible fatal CHD No known nonatherosclerotic cause, and mode of death consistent
with CHD in the absence of signiﬁcant valvular heart disease
or nonischemic cardiomyopathy
2. Cerebrovascular disease Nontraumatic intracerebral haemorrhage or infarction
3. Other atherosclerotic disease Atherosclerotic disease other than CHD or cerebrovascular disease
(including ruptured abdominal aortic aneurysm, peripheral vascular
disease, and visceral vascular disease)
4. Other cardiovascular disease CVD other than 1–3 (including valvular heart disease, nonischemic
cardiomyopathy, endocarditis, hypertensive renal disease,
pulmonary embolism, ruptured thoracic aortic aneurysm,
and complications from cardiovascular interventions other than 1–3)
5. Noncardiovascular disease All other causes of death other than 1–4 (including natural, due to trauma,
suicide, and death of unknown or uncertain cause)
MI myocardial infarction, CHD coronary heart disease, CVD cardiovascular disease
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123coronary artery disease), MI (fatal and nonfatal), and fatal
CHD. Second, ‘hard CHD’ is deﬁned as MI (fatal and
nonfatal) and fatal CHD. Heart failure morbidity and
unrecognized MI are not part of the combined CHD deﬁ-
nitions, unless otherwise noted.
Heart failure
The presentation and etiology of heart failure is heteroge-
neous [46]. Strict case deﬁnition and diagnostic criteria for
follow-up studies are therefore of utmost importance.
Methods on event adjudication of prevalent and incident
heart failure for the Rotterdam Study have been described
previously[47,48].Thediagnosisofheartfailureisclassiﬁed
as deﬁnite, probable, possible or unlikely. Deﬁnite heart
failure is deﬁned as a combination of the presence of typical
symptoms or signs of heart failure, such as breathlessness at
rest or during exertion, ankle edema, and pulmonary crepita-
tions,conﬁrmedbyobjectiveevidenceofcardiacdysfunction
(chest X-ray, echocardiography). This deﬁnition is in accor-
dance with thecriteriaoftheEuropean SocietyofCardiology
(ESC)[46].Also,fordeﬁniteheartfailure,thediagnosishasto
have been made by a medical specialist, preferably a cardi-
ologist or an internist. Heart failure is classiﬁed as probable
whenatleasttwotypicalsymptomssuggestiveofheartfailure
are present, and at least one of the following: history of CVD
(e.g., MI, valvular heart disease, hypertension), positive
response to initiated treatment for heart failure, or objective
evidence of cardiac dysfunction, while symptoms cannot be
attributed to another underlying disease, such as chronic
obstructive pulmonary disease. Heart failure is classiﬁed as
possible when one of the criteria for probable heart failure
cannot be met. For both probable and possible heart failure, a
diagnosis ofa GPora nursing homephysician sufﬁces.Heart
failureisconsideredunlikelyifsymptomsorsignsarepresent,
but when objective evidence fails to show cardiac dysfunc-
tion, and if symptoms or signs can be attributed to another
underlying disease. In accordance with the ESC guidelines,
only deﬁnite and probable cases are used in the Rotterdam
Study deﬁnition [46]. Inclusion of probable heart failure
dependsontheresearchquestionathandandisdetailedinthe
methods of the corresponding analyses. A participant is not
considered as having heart failure, if heart failure occurs
directly postoperative after cardiac surgery. For participants
of the original Rotterdam Study cohort, the presence of heart
failure at baseline is based on clinical information from the
medical records for all participants and by using a validated
score,similartothedeﬁnitionofheartfailurebytheESC[46,
47, 49]. In subsequent cohorts, the medical records of all
participants are screened for prevalent heart failure. The
presenceofheart failure duringfollow-upisbased on clinical
information from the medical records. The date of incident
heart failure is deﬁned as the date of the ﬁrst occurrence of
symptoms suggestive of heart failure, obtained from the
medicalrecords,orthedayofreceiptofaﬁrstprescriptionfor
aloopdiureticoranangiotensin-convertingenzymeinhibitor,
whichever comes ﬁrst.
Cardiac arrhythmia
Atrial ﬁbrillation and atrial ﬂutter
AF and atrial ﬂutter are the most common sustained cardiac
arrhythmia and are well known risk factors for stroke and
mortality [50]. Within the Rotterdam Study both AF and
atrial ﬂutter are one outcome and referred to as AF, given
the likewise natural course [51].
Methods on follow-up and event adjudication of prevalent
and incident AF for the Rotterdam Study have been described
previously [50]. In accordance with the ESC guidelines, an
ECG that veriﬁes the diagnosis for all potential cases of AF is
required [52]. A participant is not considered as having AF, if
AF occurs during the process of dying and is not the cause of
death, or if transient AF occurs during a MI or directly post-
operativeaftercardiopulmonarysurgery.ThepresenceofAFat
baseline is based on clinical information from the medical
records for all participants of the Rotterdam Study. Addition-
ally, at baseline a resting ECG is obtained using the afore-
mentionedmethodsandanalysessoftware(MEANS).Notably,
MEANS is characterized by a high sensitivity (96.6%) and a
high speciﬁcity (99.5%) in coding arrhythmias [26]. To verify
the diagnosis of AF, all ECGs with a diagnosis of AF or atrial
ﬂutter or any other rhythm disorder are recoded independently
by two research physicians who are blinded to the MEANS
diagnosis. The judgment of a cardiologist is asked and taken as
decisiveincaseofpersistentdisagreement.ThepresenceofAF
during follow-up is based on ECG evidence from the medical
records. Furthermore, cases of newly diagnosed AF are
obtained during the follow-up examinations at the research
center and by accessing the hospital discharge diagnoses data
fromtheNationwideMedicalRegistry.ThedateofincidentAF
is deﬁned as the date of the ﬁrst occurrence of symptoms sug-
gestiveofAFwithsubsequentECGveriﬁcation,obtainedfrom
themedicalrecords.Whendiagnosedattheresearchcenterand
no other information on a diagnosis of AF is available from
either the GPs’ ﬁles and/or the Nationwide Medical Registry,
the date of onset of AF is deﬁned as the midpoint of the time
interval between examination at which AF is detected and the
previous examination at the research center.
Sudden cardiac death
ThetermSCDiscommonlyusedforamodeofcardiacdeath.
Theclinicalpresentationofsuddencardiacdeathisfrequently
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involved. The underlying etiology can be diverse, but most
often results from tachyarrhythmia or mechanical complica-
tions of MI [53]. SCD is an outcome of special interest in
studies on genetics, certain ECG parameters, and pharmaco-
logical adverse effects on the heart [54–56].
During the past century there has been some debate on
the deﬁnition of this clinical presentation of heart disease,
however Meyerburg’s deﬁnition has been accepted and
endorsed widely: ‘‘A natural death due to cardiac causes,
heralded by abrupt loss of consciousness, within 1 h after
the onset of acute symptoms or an unwitnessed, unexpected
death of someone seen in a stable medical condition less
than 24 h previously with no evidence of a non-cardiac
cause’’ [53, 57].
Within the Rotterdam Study the methods of adjudicating
SCD are based on the deﬁnition supported by the ESC and
have been described previously [53, 55]. All available infor-
mationfromGPsandacopyofthemedicalrecordsareusedto
assess if the death can be classiﬁed as a SCD using the
aforementioned deﬁnition proposed by Meyerburg [53, 57].
First, potential cases are subdivided on the basis whether the
deathiswitnessed.Ifdeathiswitnessedandoccurswithinone
hourafterthestartofsymptoms(ifpresent)itisassumedtobe
a SCD,without additionalreviewofthe medical recordsfor a
medical history of CVD. In case of an unwitnessed death,
evidence of underlying cardiac or noncardiac causes is sear-
ched for. Inclusion of unwitnessed SCD in the Rotterdam
Studydeﬁnitiondependsontheresearchquestionathand.The
date of death is established from the medical records or
municipality records.
Discussion
Comparability
The necessity of research on the etiology and prognosis of
heart disease has been obvious for many decades. This has
resulted in countless epidemiological studies with a focus
on CHD or CVD at large, which is represented by the
recent cardiovascular research presented in EJE [58–74].
However, multiple, and sometimes inconsistent, deﬁnitions
of cardiac outcomes are in use. For instance, the inclusion
of stable or unstable angina pectoris, coronary revascular-
ization procedures, and speciﬁc subtypes of CHD mortality
varies greatly in overall CHD outcome deﬁnitions. This
may inﬂuence the conclusions drawn and impede the
overall comparability of studies on CHD.
A substantial proportion of the CHD mortality occurs out-
of-hospital[39].Classiﬁcationofout-of-hospitaldeathisoften
based on limited information, due to its sudden onset or
unwitnessedoccurrence.Therefore,aclearcodingsystemisof
key importance. Various classiﬁcations by the World Health
Organization(WHO),usingdatafromdeathcertiﬁcates,orself
developed CHD mortality deﬁnitions are used in epidemio-
logical and clinical research. Within the Rotterdam Study,
ICD-10 has been the classiﬁcation of choice during the past
decade for fatal and nonfatal events [40, 41]. However, the
ICD-10 causes confusion when coding mortality. ICD-10
containscodesforbothunderlyingdisease(causeofdeath),as
well as mechanisms and circumstances of dying (mode of
death). For instance, cardiac arrest (code I46), heart failure
(code I50), sudden death (code R96), and unattended death
(code R98) could very well be attributed to CHD as to other
conditions, depending on ones individual medical history.
More recently, in order to avoid confusion and enhance
comparabilityinourmultiplelargetransatlanticcollaborations
withotherepidemiologicstudies,aclassiﬁcationusedbyother
large cardiovascular cohort studies has been adopted by the
Rotterdam Study [11, 12, 75]. As mentioned before, this
classiﬁcation has been proposed as the international standard
for epidemiological research [31]. As a consequence, harmo-
nization of the outcome deﬁnitions used in our large epide-
miologic collaborations will strengthen the consistency of
futureresults.Furthermore, the categorizationofthe events as
suchhelpstoavoidinaccuracyintheimmediatecauseofdeath
reporting, complicated by the presence of comorbid condi-
tions, particularly in the elderly [43]. Therewith, this classiﬁ-
cation allows for more accurate adjudication of the cause of
death by underlying etiology and result in less
misclassiﬁcation.
Variability
Insight into outcome deﬁnitions does not only facilitate
comparability between studies, it may also explain vari-
ability between or even within studies. Reported incidences
of CVD vary over different geographic areas and may
reﬂect differences in presence of risk factors, active treat-
ment, and differences in CVD susceptibility among popu-
lations. However, the differences may also be a result of
differences in coding systems used or differences in clini-
cal practice of adjudication of events [76]. In a recent
report on the WHO Burden of Disease Program the inci-
dence of fatal ischemic heart disease varied greatly. For
instance, incidence of fatal ischemic heart disease was
reported to be 54 per 100,000 in The Netherlands, and 98
per 100,000 in the United States, accounting for 11.3% and
17.9% of the total mortality, respectively. Besides trans-
atlantic differences, great dissimilarities among neighbor-
ing nations in Western Europe were observed. Incidences
of fatal ischemic heart disease varied from 38 per 100,000
in France to 90 per 100,000 in both Germany and the
United Kingdom [77]. Despite the fact that all countries
applied the same WHO coding system for adjudication of
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123the causes of death, such differences in incidences are
unlikely to be fully explained just by variation in presence
and management of cardiovascular risk factors. The precise
cause of this variability remains uncertain.
Variability in incidences is also known to occur within
the same study. It is well known that calendar time is a
cause of variability in observed incidences of heart disease
in a single study population due to changes in prevalence or
treatment of risk factors, or introduction of novel sensitive
diagnostics over time (e.g. creatinin kinase MB, troponins)
[78]. Furthermore, researchers may decide on including
outcomes of various certainties (e.g. deﬁnite, probable).
Depending on the research question at hand, more or less
sensitive criteria may be applied in different analyses.
Next, one should also be aware that a study population is of
higher average health status at baseline of a study or shortly
after an active repeat research center visit [79]. After all,
those who attend in a visit to a research center are neces-
sarily healthy enough to undergo the examinations.
Quality control
In The Netherlands, many studies on incidence and prog-
nosis of heart disease rely on data provided by the
Nationwide Medical Registry. This registry includes all
discharge diagnoses for every hospital admission in The
Netherlands and has shown a good sensitivity and good
positive predictive value for acute CHD diagnoses, but less
for chronic conditions such as heart failure [80]. Within the
Rotterdam Study, a validation study for evaluating the
clinical follow-up event registration of incident MI was
performed. This was done by obtaining data on hospital
discharge diagnoses in Rotterdam Study participants from
the Nationwide Medical Registry. A total of 100 discharge
diagnoses of MI were obtained from the registry. In 59
instances MI was the primary discharge diagnosis, and in
41 instances MI was mentioned as a secondary discharge
diagnosis. These 100 hospitalized MIs were compared to
incident events observed through our clinical follow-up
system and this showed that none of the primary diagnoses
were missed and only two of the secondary discharge
diagnoses were not detected, resulting in a 98% case
ﬁnding of hospitalized MIs in our study population.
Strengths and limitations
Within the Rotterdam Study we have over two decades of
experience in data collection. It is known that use of various
sources for data collection is needed to achieve complete
follow-up in large epidemiologic studies [81]. Within the
Rotterdam Study, multiple sources for potential events are
consulted, namely the linkage of the medical records and
pharmacy data to the study database, regular screening of
medical records at the GPs’ ofﬁce, follow-up interviews and
examination at the research center, and consultation of the
central registry of the local municipality (Table 1). The Rot-
terdamStudytherebyhasavirtuallycompletefollow-upwith
respect to vital status: using the sources described above,
exactly 22 years after start of the study, less than 1.8% of the
participants have been lost to follow-up. This is predomi-
nantly due to emigration.
At initiation of the Rotterdam Study most GPs in the
research area were already using standardized digital patient
records, resulting in over 85% of the enrolled participants
having their medical record digitally linked to the study
database [20]. Still, 22 years after initiation of the study, the
greatmajority(79%)ofallparticipants aliveareenlistedwith
a GP with linkage to the automated follow-up system. This
resultsinhighqualitydocumentation.Furthermore,theGPsin
the research area have a low threshold to refer patients for
community based laboratory testing and (exercise) ECGs.
However,thisdoesnotfullyapplytotheparticipantslivingin
nursing homes. Predominantly, the oldestof old and diseased
participants are less likely to undergo diagnostic tests (e.g.
ECG, echocardiography, cardiac biomarker testing), or to get
referred to a medical specialist in comparison to elderly in
other European countries [82]. This is usually due to lack of
diagnostic accuracy of physical examination and reduced
mobility of the nursing home residents [83]. Moreover, clin-
icalbeneﬁtisuncertainandcareforothercomorbidconditions
(such as Parkinson’s disease or advanced dementia) is con-
sideredtotakepriorityoverperformingdiagnosticprocedures
outside the nursing home [84, 85]. In all, this may result in
missing nonhospitalized nonfatal events in nursing home
residents.
Althoughnowadaysthetypicalcardiacpatientisofoldage,
elderly persons are still highly underrepresented in cardio-
vascularresearch[86,87].TheRotterdamStudyhasnoupper
age limit and can thereby study the determinants and out-
comes of heart disease in older participants. This implies
challenges in adjudication of diagnosis of especially chronic
diseases (e.g. heart failure), which are associated with a wide
range of comorbid conditions [88, 89]. Symptoms of other
common disease in older individuals, such as chronic
obstructive pulmonary disease and chronic venous insufﬁ-
ciency, can be easily misattributed to the failing heart. Strict
case deﬁnitions are therefore insurmountable in order to pre-
vent misadjudication, however this may result in missing
some cases where limited information is available.
Conclusion
The need for studying occurrence and prognosis of heart
disease is obvious. Case ﬁnding in epidemiological studies
is strongly depending on the availability of various sources
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123of clinical follow-up and clear outcome deﬁnitions. The
presentation of the up-to-date deﬁnitions of cardiac out-
comes in epidemiologic studies will result in enhanced
possibilities to compare results with other studies in the
ﬁeld of cardiovascular research and may increase the
strength of future collaborations.
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